FDAnews Drug Daily Bulletin

Congress is pointing a finger at the FDA for spurring the increase in drug shortages through stepped up enforcement actions, despite the agency’s efforts to mitigate the trend. FDA regulatory activity has effectively shut down 30 percent of the manufacturing capacity at America’s four largest producers of generic injectables — Bedford Laboratories, Sandoz, Teva Pharmaceuticals and Hospira — a congressional report states. Generic injectables are involved in the majority of drug shortages.
Washington Drug Letter